Nurix Therapeutics
NRIX
106 hedge funds and large institutions have $568M invested in Nurix Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 46 increasing their positions, 30 reducing their positions, and 22 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 30
10.07% more ownership
Funds ownership: 90.03% → 100.1% (+10%)
0% more capital invested
Capital invested by funds: $566M → $568M (+$2.5M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9% less funds holding
Funds holding: 117 → 106 (-11)
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$27.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$16.2M |
| 3 |
BlackRock
New York
|
+$9.42M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$8.12M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.58M |
Top Sellers
NRIX Hedge Fund Activity: Q2 2022 in Review
106 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2022, worth a combined $568M — up 0.44% from $566M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of NRIX and 13 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 46 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $27.6M. The largest seller was Wellington Management Group, cutting an estimated $8.95M.
- 106 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2022, down from 117 in Q1 2022.
- Funds reported $568M of Nurix Therapeutics stock for Q2 2022, up 0.44% quarter-over-quarter.
- 13 funds opened new Nurix Therapeutics positions in Q2 2022 and 22 closed out, a net change of -9 holders.
- The largest Nurix Therapeutics buyer in Q2 2022 was Deep Track Capital, an estimated $27.6M added.
- The largest Nurix Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $8.95M sold.
Based on aggregated 13F filings for Q2 2022.